Pharmacorp enters definitive deals for two pharmacies

Executive Summary

• Pharmacorp Rx Inc. has entered into definitive share purchase agreements to acquire 100% interest in two Pharmachoice Canada bannered pharmacies in Western Canada, including associated lands and building for one location.
• The total aggregate purchase price is $3.4 million, payable 75% in cash and 25% via issuance of common shares.
• The transaction is expected to close on or about October 1, 2025, subject to customary conditions.

Key Details

• Target Assets: Two Pharmachoice Canada bannered pharmacies in Western Canada; one includes associated lands and building.
• Purchase Price: Aggregate $3.4 million, subject to customary adjustments.
• Consideration Structure:
  • 75% paid in cash on hand.
  • 25% paid via issuance of common shares of Pharmacorp.
• Share Pricing Mechanism: The deemed price for common shares is equal to the volume-weighted average trading price (VWAP) on the TSX Venture Exchange during the 10-day period ending at the close of business on the third business day prior to the closing date.
• Closing Date: Expected on or about October 1, 2025.
• Fees: No finders' fees are payable.
• Strategic Context: Transactions align with previously announced letters of intent and the strategic alliance with Pharmachoice Canada.

Notable Quotes

• "These transactions reflect our ability to originate, negotiate and close accretive acquisitions as initially signalled in our previously announced letters of intent. They underscore our internal capacity to convert opportunities from the strategic alliance with Pharmachoice Canada into tangible growth." — Alan Simpson, Executive Chair of Pharmacorp